Quote:

---

i think, going off Madrigal's thinking, one way we can know whether or not to continue with leronlimab treatment would be through the use of only one biomarker, T4.

---

T4 is a good biomarker but the disease is more complex than just that. We will want to base it off of all biomarkers and more importantly the results of cT1 and PDFF. Reductions in fibrosis are what will actually show how effective leronlimab is and the whole host of biomarkers will show why it is effective.